Latest news
Pancreatic Cancer Is Forcing Regulators to Move Faster
EMA has started a phased review of daraxonrasib in pancreatic cancer, while Revolution Medicines says its U.S. rolling NDA is nearing completion. The science is moving into the regulatory fast lane. Access systems are not ready yet.
Cardio-oncology demand is rising, but training gaps are holding systems back
Cholesterol prevention is moving earlier. Is Europe ready to treat inherited risk before adulthood?
IPM Brief – Issue 5 | Breakthroughs Don’t Deliver Themselves
Prostate Cancer Access Moves Into the Veterans System
Gastric Cancer Gets a New Biomarker Access Signal
The Brain Can Recover. The System Often Does Not Let It.
CIDP Treatment Moves Beyond the IVIg Default
Ebola Modelling Shows the Outbreak May Be Bigger Than the Count
Court Fight Over ACIP Turns Vaccine Advice Into an Access Risk
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.